Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease

Journal of the National Cancer Institute

Volumn 88, Issue 11, 1996, Pages 747-753

  Rybak, Susanna M ^a   Pearson, John W ^a   Fogler, William E ^a   Volker, Kirk ^b   Spence, Sally E ^b   Newton, Dianne L ^b   Mikulski, Stanislaw M ^c   Ardelt, Wojciech ^c   Riggs, Charles W ^d   Kung, Hsiang Fu ^a   Longo, Dan L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NCI FCRDC   (United States)

^c Alfacell Corporation   (United States)

^d Data Management Services Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; DOXORUBICIN; GLYCOPROTEIN P; RANPIRNASE; RIBONUCLEASE A; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; COLON CARCINOMA; CONTROLLED STUDY; CROSS RESISTANCE; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DRUG RESISTANCE; EGG PROTEINS; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RIBONUCLEASES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 15844415446     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.11.747     Document Type: Article

References (27)

1. Ardelt W, Mikulski SM, Shogen K. Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. J Biol Chem 1991;266:245-51.
2. Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ, Shogen K. Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent. Cell Tissue Kinet 1988;21:169-82.
3. Mikulski SM, Viera A, Ardell W, Menduke H, Shogen K. Tamoxifen and trifluoroperazine (Stelazine) potentiate cytostatic/cytotoxic effects of P-30 protein, a novel protein possessing anti-tumor activity. Cell Tissue Kinet 1990;23:237-46.
4. Mikulski SM, Ardelt W, Shogen K, Bernstein EH, Manduke H. Striking increase of survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos. J Natl Cancer Inst 1990;82:151-3.
5. Mikulski SM, Grossman AM, Carter PW, et al. Phase I human clinical trial of Onconase (P-30 protein) administered intravenously on a weekly schedule in cancer patients with solid tumors. Int J Oncol 1993;3:57-64.
6. Lin JJ, Newton DL, Mikulski SM, Kung HF, Youle RJ, Rybak SM. Characterization of the mechanism of cellular and cell free protein synthesis inhibition by an anti-tumor ribonuclease. Biochem Biophys Res Commun 1994;204:156-62.
7. Wu Y, Mikulski SM, Ardelt W, Rybak SM, Youle RJ. Cytotoxic ribonuclease. Study of the mechanism of Onconase cytotoxicity. J Biol Chem 1993;268:10686-93.
8. Mikulski SM, Viera A, Shogen K. In vitro synergism between a novel amphibian oocytic ribonuclease (Onconase) and tamoxifen, lovastatin and cisplatin in human OVCAR-3 ovarian carcinoma cell line. Int J Oncol 1992; 1:779-85.
9. Chun H, Costanzi J, Mittleman A, Panella T, Puccio C, Coombe N. et al. Phase I/II trial of Onconase plus tamoxifen in patients with advanced pancreatic carcinoma. Proc ASCO 1995;14:210.
10. Fork JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990;42:155-99.
11. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med 1987;316:1388-93.
12. Endicott JA, Ling V. The biochemistry of Pglycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989;58:137-71.
13. Wadler S, Schwanz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990;50:3473-86.
14. Fogler WE, Pearson JW, Volker K, Ariyoshi K, Watabe H, Riggs CW, et al. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody [see comment citation in Medline]. J Natl Cancer Inst 1995;87:94-104.
15. Hamada H, Tsuruo T. Functional role for the 170- to 180-kDa glycoprotein specific to drugresistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 1986;83:7785-9.
16. Fairchild CR, Ivy SP, Kao-Shang CS, Whang-Peng J, Rosen N, Israel MA, et al. Isolation of amplified and overexpressed DNA sequences from Adriamycin-resistant human breast cancer cells. Cancer Res 1987;47:5141-8.
17. Pearson JW, Fogler WE, Volker K, Usui N, Goldenberg SK, Gruys E, et al. Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. J Natl Cancer Inst 1991;83:1386-91.
18. Rybak SM, Saxena SK, Ackerman EJ, Youle RJ. Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins. J Biol Chem 1991;266:21202-7.
19. Mosmann T. Rapid colorimetric assay for cellular growth and survival; application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
20. Rittmann-Grauer LS, Yong MA, Sanders V, Mackensen DG. Reversal of Vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft. Cancer Res 1992;52:1810-6.
21. Cox DR. Regression models and life table analysis. J R Stat Soc Ser B 1972;34:187-220.
22. Thomas DG, Breslow N, Gart JJ. Trend and homogeneity analyses of proportions and life table data. Comput Biomed Res 1977;10:373-81.
23. Webb JL. Enzymes and metabolic inhibitors. Vol 1. New York: Academic Press, 1963:487-512.
24. Valeriote F. Lin HS. Synergistic interaction of anticancer agents: a cellular perspective. Cancer Chemother Rep 1975;59:895-900.
25. Hu XF, Martin TJ, Bell DR, de Louise M, Zalcberg JR. Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines [see comment citation in Medline]. Cancer Res 1990; 50:2953-7.
26. Chou TC, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 1983;4:450-4.
27. Ganapathi R, Hercbergs A, Grabowski D, Ford J. Selective enhancement of vincristine cytotoxicity in multidrug-resistant tumor cells by Dilantin (phenytoin) [published erratum appears in Cancer Res 1993;53:6079], Cancer Res 1993;53:3262-5.